# Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Study · id `cardio:ct-nct01117987` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01117987](<https://clinicaltrials.gov/study/NCT01117987>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01117987

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 144 participants.

## Technical summary

Registry record NCT01117987. Non-randomized; no masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-05-21.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 144 participants (enrolled count; ClinicalTrials.gov record NCT01117987, source copy `cardio:ctgov-nct01117987-2015-08-13`, retrieved 2026-10-31)
- Start date: 2010-04 (registry gives no type) (ClinicalTrials.gov record NCT01117987, source copy `cardio:ctgov-nct01117987-2015-08-13`, retrieved 2026-10-31)
- Primary completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01117987, source copy `cardio:ctgov-nct01117987-2015-08-13`, retrieved 2026-10-31)
- Completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01117987, source copy `cardio:ctgov-nct01117987-2015-08-13`, retrieved 2026-10-31)
- Results first posted: 2015-05-21 (ClinicalTrials.gov record NCT01117987, source copy `cardio:ctgov-nct01117987-2015-08-13`, retrieved 2026-10-31)
- Countries: United States; Austria; Belgium; Canada; France; Germany; Italy; Japan; Netherlands; South Korea; Spain; Switzerland; United Kingdom (ClinicalTrials.gov record NCT01117987, source copy `cardio:ctgov-nct01117987-2015-08-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01117987-2015-08-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
- Acronym: IMPRES Extn
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Imatinib
- Intervention (Drug): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 8e260a7dc22e53b21308130c125fd645bf6cffa27d86524d96b24d5aca1fc19d
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
